LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced upcoming presentations featuring LNZ100, their aceclidine-based eye drop for presbyopia treatment, at major ophthalmology and optometry conferences. Presentations include:
1. Eyecelerator at AAO 2024 (October 17, 2024): CLARITY Phase 3 study data of LNZ100
2. Academy 2024 Indianapolis (November 7, 2024): Analysis of pupil size impact on vision improvement with aceclidine
3. Academy 2024 Indianapolis (November 7, 2024): Poster presentation on positive Phase 3 presbyopia trial data
LENZ has submitted a New Drug Application (NDA) to the FDA for LNZ100, a preservative-free, single-use, once-daily eye drop containing aceclidine. The product achieved all primary and secondary endpoints in the Phase 3 CLARITY study for presbyopia treatment.
LENZ Therapeutics (Nasdaq: LENZ), un'azienda biofarmaceutica in fase clinica avanzata, ha annunciato presentazioni imminenti che riguardano LNZ100, il loro collirio a base di aceclidina per il trattamento della presbiopia, in importanti conferenze di oftalmologia e optometria. Le presentazioni includono:
1. Eyecelerator all'AAO 2024 (17 ottobre 2024): dati dello studio CLARITY di fase 3 su LNZ100
2. Academy 2024 Indianapolis (7 novembre 2024): analisi dell'impatto delle dimensioni della pupilla sul miglioramento della visione con aceclidina
3. Academy 2024 Indianapolis (7 novembre 2024): presentazione poster sui dati positivi dello studio di fase 3 sulla presbiopia
LENZ ha presentato una Nuova Domanda di Farmaco (NDA) alla FDA per LNZ100, un collirio monouso, senza conservanti, da utilizzare una volta al giorno contenente aceclidina. Il prodotto ha raggiunto tutti gli obiettivi primari e secondari nello studio CLARITY di fase 3 per il trattamento della presbiopia.
LENZ Therapeutics (Nasdaq: LENZ), una empresa biofarmacéutica en etapa clínica avanzada, anunció próximas presentaciones sobre LNZ100, su colirio a base de aceclidina para el tratamiento de la presbicia, en importantes conferencias de oftalmología y optometría. Las presentaciones incluyen:
1. Eyecelerator en la AAO 2024 (17 de octubre de 2024): datos del estudio CLARITY fase 3 de LNZ100
2. Academy 2024 Indianápolis (7 de noviembre de 2024): análisis del impacto del tamaño de la pupila en la mejora de la visión con aceclidina
3. Academy 2024 Indianápolis (7 de noviembre de 2024): presentación de póster sobre los datos positivos del ensayo de fase 3 para la presbicia
LENZ ha presentado una Solicitud de Nuevo Medicamento (NDA) a la FDA para LNZ100, un colirio de un solo uso, sin conservantes, que se aplica una vez al día y contiene aceclidina. El producto logró todos los objetivos primarios y secundarios en el estudio CLARITY fase 3 para el tratamiento de la presbicia.
LENZ Therapeutics (Nasdaq: LENZ), 임상 단계 후반의 생명과학 회사,는 노안 치료를 위한 aceclidine 기반 안약 LNZ100에 대한 발표가 주요 안과 및 검안학 회의에서 있을 것이라고 발표했습니다. 발표 내용은 다음과 같습니다:
1. AAO 2024에서 Eyecelerator (2024년 10월 17일): LNZ100의 CLARITY 3상 연구 데이터
2. Academy 2024 인디애나폴리스 (2024년 11월 7일): aceclidine에 의한 시력 개선에 대한 동공 크기 영향 분석
3. Academy 2024 인디애나폴리스 (2024년 11월 7일): 3상 노안 시험 데이터에 대한 포스터 발표
LENZ는 FDA에 LNZ100에 대한 신약 신청(NDA)을 제출했습니다. 이 제품은 aceclidine이 함유된 하루 한 번 사용하는 보존제가 없는 단일 용도 안약입니다. 이 제품은 노안 치료를 위한 CLARITY 3상 연구에서 모든 주요 및 부차적 목표를 달성했습니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase clinique avancée, a annoncé des présentations à venir sur LNZ100, leur collyre à base d'aceclidine pour le traitement de la presbytie, lors de grandes conférences d'ophtalmologie et d'optométrie. Les présentations comprennent :
1. Eyecelerator à l'AAO 2024 (17 octobre 2024) : données de l'étude CLARITY de phase 3 sur LNZ100
2. Academy 2024 Indianapolis (7 novembre 2024) : analyse de l'impact de la taille de la pupille sur l'amélioration de la vision avec l'aceclidine
3. Academy 2024 Indianapolis (7 novembre 2024) : présentation affichée sur les données positives de l'essai de phase 3 pour la presbytie
LENZ a soumis une Demande de Nouveau Médicament (NDA) à la FDA pour LNZ100, un collyre à usage unique, sans conservateurs, à appliquer une fois par jour contenant de l'aceclidine. Le produit a atteint tous les objectifs primaires et secondaires dans l'étude CLARITY de phase 3 pour le traitement de la presbytie.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat bevorstehende Präsentationen zu LNZ100, ihrem auf Aceclidin basierenden Augentropfen zur Behandlung von Presbyopie, auf wichtigen Augenheilkunde- und Optometriekonferenzen angekündigt. Die Präsentationen umfassen:
1. Eyecelerator auf der AAO 2024 (17. Oktober 2024): Daten der CLARITY Phase 3-Studie zu LNZ100
2. Academy 2024 Indianapolis (7. November 2024): Analyse der Auswirkungen der Pupillengröße auf die Sehverbesserung mit Aceclidin
3. Academy 2024 Indianapolis (7. November 2024): Posterpräsentation über positive Phase 3-Daten der Presbyopie-Studie
LENZ hat der FDA einen Antrag auf Zulassung eines neuen Medikaments (NDA) für LNZ100 vorgelegt, ein konservierungsmittelfreies Einmal-Augenmittel, das Aceclidin enthält und einmal täglich angewendet wird. Das Produkt hat alle primären und sekundären Endpunkte in der CLARITY Phase 3-Studie zur Behandlung der Presbyopie erreicht.
- LNZ100 achieved all primary and secondary endpoints in the Phase 3 CLARITY study
- LENZ has submitted a New Drug Application (NDA) to the FDA for LNZ100
- Upcoming presentations at major ophthalmology and optometry conferences to showcase LNZ100 data
- None.
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced presentations featuring LNZ100 at multiple upcoming ophthalmology and optometry medical conferences, including Eyecelerator at the 2024 American Academy of Ophthalmology (AAO) Annual Meeting on October 17, 2024 and Academy 2024 Indianapolis, presented by the American Academy of Optometry on November 6–9, 2024.
| Eyecelerator at AAO 2024 presentation | ||
| Title: | CLARITY Phase 3 study data of LNZ100 for the treatment of presbyopia | |
| Format: | Oral presentation | |
| Presenter: | Marc Odrich, MD, Chief Medical Officer, LENZ Therapeutics | |
| Day/Time: | Thursday, October 17, 2024; 1:15pm CT | |
| Session: | Anterior Segment Company Showcase, Room 353c | |
| Location: | McCormick Place, Chicago, Illinois | |
| Academy 2024 Indianapolis (American Academy of Optometry) | ||
| Title: | Analysis of Pupil Size Impact on Near and Distance Vision Improvement Following Administration of Aceclidine, a Pupil-Selective Miotic | |
| Format: | Oral presentation | |
| Presenter: | Barry Eiden, OD, FAAO, FSLS, Senior Advisor for Professional Relations, LENZ Therapeutics | |
| Day/Time: | Thursday, November 7, 2024; 2:45pm – 3pm CT | |
| Session: | Room 201-202 | |
| Location: | Indianapolis Convention Center & Lucas Oil Stadium, Indianapolis, Indiana | |
| Academy 2024 Indianapolis (American Academy of Optometry) | ||
| Title: | Aceclidine, a Pupil- Selective Miotic, Demonstrates Positive Topline Data in Phase 3 Presbyopia Trials | |
| Format: | Poster presentation (Poster #35) | |
| Presenter: | Barry Eiden, OD, FAAO, FSLS, Senior Advisor for Professional Relations, LENZ Therapeutics | |
| Day/Time: | Thursday, November 7, 2024; 4:30pm – 6:30pm CT | |
| Session: | (POS-01) Scientific Program Poster Session, Exhibit Hall H | |
| Location: | Indianapolis Convention Center & Lucas Oil Stadium, Indianapolis, Indiana | |
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 achieved all primary and secondary endpoints in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the treatment of presbyopia. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
What is LENZ Therapeutics' stock symbol?
What is LNZ100 and what is it used for?
When and where will LENZ Therapeutics present data on LNZ100?
Has LENZ Therapeutics submitted an NDA for LNZ100?
